ZYLET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZYLET (ZYLET).
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
| Metabolism | Loteprednol etabonate is hydrolyzed to inactive metabolites by esterases in the eye and systemically. Tobramycin is primarily excreted unchanged in urine. |
| Excretion | Renal (30% unchanged), biliary/fecal (70% as metabolites) |
| Half-life | ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing. |
| Protein binding | Loteprednol: ~70% bound to albumin; Tobramycin: negligible (<10%) protein binding. |
| Volume of Distribution | Loteprednol: ~2.5 L/kg (systemic); Tobramycin: ~0.26 L/kg (systemic). Clinical meaning: loteprednol widely distributed, tobramycin mainly extracellular. |
| Bioavailability | Ocular suspension: systemic bioavailability is low (<1% for both components) due to local administration and metabolism. |
| Onset of Action | Ocular: anti-inflammatory effect within 24-48 hours; antibacterial effect within 1-2 hours after instillation. |
| Duration of Action | Ocular: anti-inflammatory and antibacterial effects persist for duration of therapy; clinical improvement typically within 3-5 days. |
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dose adjustment required based on GFR as systemic absorption is minimal. |
| Liver impairment | No dose adjustment required based on Child-Pugh class as systemic absorption is minimal. |
| Pediatric use | Children ≥2 years: same as adult dosing. Safety and efficacy in children <2 years not established. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to increased risk of ocular adverse effects from chronic corticosteroid use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZYLET (ZYLET).
| Breastfeeding | It is not known whether loteprednol or tobramycin are excreted in human milk. Caution should be exercised when administered to a nursing woman. Consider the risk of infant exposure to corticosteroids and fluoroquinolones. M/P ratio not available. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, systemic corticosteroids and fluoroquinolones (including loteprednol and tobramycin) have shown adverse effects on fetal development at high doses. Avoid use during pregnancy unless potential benefit outweighs risk; use only if clearly needed. |
■ FDA Black Box Warning
None
| Common Effects | Skin rash Diarrhea Nausea |
| Serious Effects |
["Hypersensitivity to any component","Epithelial herpes simplex keratitis (dendritic keratitis)","Viral diseases of the cornea and conjunctiva, including vaccinia and varicella","Mycobacterial infection of the eye","Fungal diseases of ocular structures"]
| Precautions | ["Prolonged use may lead to ocular hypertension/glaucoma, cataract formation, secondary infections, and delayed wound healing","Risk of bacterial resistance with prolonged use","Not for injection","Use with caution in patients with herpes simplex keratitis"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of maternal hypersensitivity reactions or ocular adverse effects. No specific fetal monitoring required beyond routine prenatal care unless prolonged systemic exposure occurs. |
| Fertility Effects | No known adverse effects on fertility in human studies. Animal studies with fluoroquinolones have shown no impairment of fertility at clinically relevant doses. |